The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> August 12, 2016

Interview with the CFO, Treasurer & Secretary: Aytu BioScience, Inc. (OTCMKTS:AYTU)

Gould, Greg
Greg Gould, CPA, is Chief Financial Officer, Treasurer and Secretary at Aytu BioScience, Inc. Mr. Gould has held senior management positions in the life sciences industry for over 20 years. Prior to the formation of Aytu BioScience, Inc., he provided financial and operational consulting services to the biotech industry through his consulting company, Gould LLC, from April 2012 until June 2014. Mr. Gould was Chief Financial Officer, Treasurer and Secretary of SeraCare from November 2006 until the company was sold to Linden Capital Partners in April 2012. During the period from July 2011 until April 2012 Mr. Gould also served as the Interim President and Chief Executive Officer of SeraCare Life Sciences. Mr. Gould has held several other executive positions at publicly traded life sciences companies including the Chief Financial Officer role at Atrix Laboratories, Inc., an emerging specialty pharmaceutical company focused on advanced drug delivery. During Mr. Gould’s tenure there, he was instrumental in the negotiation and sale of the company to QLT, Inc. for over $855M. He also played a critical role in the management of several licensing agreements including the global licensing agreement with Sanofi-Synthelabo of the ELIGARD products. Mr. Gould was the Chief Financial Officer at Colorado MEDtech, Inc., a publicly traded medical device design and manufacturing company where he negotiated the transaction to sell the company to KRG Capital Partners. Mr. Gould began his career as an auditor with Arthur Andersen, LLP. He currently serves on the board of directors of CytoDyn Inc., a publicly traded drug development company pursuing antiviral agents for the treatment of HIV. Mr. Gould graduated from the University of Colorado with a B.S. in business administration and is a Certified Public Accountant. Mr. Gould also serves as the Chief Financial Officer, Treasurer and Secretary of publicly traded Ampio Pharmaceuticals. Profile
TWST: For Aytu BioScience, can you tell us a little bit about the company and its business model?

Mr. Gould: Aytu is a company focused on urology. We went out

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
Interview with the Co-CEO and the CAO: Planet 13 Holdings Inc. (OTCMKTS:PLNH)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
Profitability Strategy Pays Off for Bank IT Company Q2 Holdings
Three Mid-Cap Names Using Their Balance Sheets to Create Value
Look Beyond Traditional Emerging Markets for More Diversification, Less Risk
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy